The spin-off RetinaReadRisk has been created for marketing software and a mobile system based on artificial intelligence to detect diabetic retinopathy in the early stages. The founding partners are IISPV, UP2Smart (URV), Grupo TRC (Telefónica) and GENESIS Biomed, a CataloniaBio & HealthTech member. The creation of the company has been carried out within the framework of a project supported by EIT Health, an aspect that also gives it an international projection.
GENESIS Biomed has acted as a Venture Building platform, has invested in the spin-off through its investment vehicle (GENESIS Tech Transfer Boost) and is currently assuming the duties of interim CEO of the company. In the words of Josep Lluís Falcó, CEO of GENESIS Biomed: "We are facing a huge opportunity that can change the paradigm of diabetic patient management, anticipating their potential evolution towards diabetic retinopathy. We offer a powerful tool that will end up leading to significant savings for the national health system."
The test to detect diabetic retinopathy is an examination of the fundus of the eye. In Catalonia it is carried out in certain primary care centers (CAP), mostly located in cities. In the future, the aim is to put the technology that will commercialize the spin- off at the service of all CAPs so that people can be explored by their doctor without the need for commute.
Photo: Domènec Puig, researcher of the ITAKA group of the Department of Computer Engineering and Mathematics of the URV and co-founder of UP2Smart; Joan Vendrell, director of the IISPV; Josep Lluís Falcó, CEO of Genesis Biomed; Pau Puig, administrator of UP2Smart; and Pere Romero, researcher in charge of the Research Group in Ophthalmology of the IISPV.
You may also be interested in:
GENESIS Biomed continues growing and adding value in biomedical sector
Comments